

-continued

&lt;400&gt; SEQUENCE: 100

Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys  
 1                      5                      10

&lt;210&gt; SEQ ID NO 101

&lt;211&gt; LENGTH: 11

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MISC\_FEATURE

&lt;222&gt; LOCATION: (1)..(1)

&lt;223&gt; OTHER INFORMATION: May or may not be present

&lt;400&gt; SEQUENCE: 101

Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys  
 1                      5                      10

&lt;210&gt; SEQ ID NO 102

&lt;211&gt; LENGTH: 9

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MISC\_FEATURE

&lt;222&gt; LOCATION: (1)..(1)

&lt;223&gt; OTHER INFORMATION: May or may not be present

&lt;400&gt; SEQUENCE: 102

Lys Leu Val Leu Asn Cys Thr Ala Arg  
 1                      5

&lt;210&gt; SEQ ID NO 103

&lt;211&gt; LENGTH: 7

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MISC\_FEATURE

&lt;222&gt; LOCATION: (1)..(1)

&lt;223&gt; OTHER INFORMATION: May or may not be present

&lt;400&gt; SEQUENCE: 103

Lys Asn Ser Thr Phe Val Arg  
 1                      5

What is claimed is:

1. A method of producing aflibercept, comprising:

- (a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM);
- (b) binding aflibercept from said clarified harvest to a Protein A resin;
- (c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said eluate has a first color;
- (d) subjecting said eluate comprising aflibercept to anion exchange chromatography (AEX); and
- (e) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color of said affinity eluate is a more intense yellow

brown color than said second color of said flowthrough fraction when said eluate and flowthrough protein concentrations are normalized.

2. The method of claim 1, wherein said first color has a b\* value ranging from about 2.0 to about 20.0 when said protein concentration is normalized to 10.0 g/L.

3. The method of claim 1, wherein said second color has a b\* value ranging from about 0.5 to about 5.0 when said protein concentration is normalized to 10.0 g/L.

4. The method of claim 1, wherein said cell is selected from a group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.